Potential drug interactions associated with treatments for Type 2 diabetes and its comorbidities: a clinical pharmacology review

References

• Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N. Engl. J. Med.348, 383–393 (2003).
   PubMed Web of Science ®Google Scholar
• Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in Type 2 diabetes. N. Engl. J. Med.358, 580–591 (2008).
   PubMed Web of Science ®Google Scholar
• Holt RI, Phillips DI, Jameson KA, Cooper C, Dennison EM, Peveler RC. The relationship between depression and diabetes mellitus: findings from the Hertfordshire cohort study. Diabetes Med.26, 641–648 (2009).
   PubMed Web of Science ®Google Scholar
• Campayo A, de Jonge P, Roy JF et al. Depressive disorder and incident diabetes mellitus: the effect of characteristics of depression. Am. J. Psychiatry167, 580–588 (2010).
   PubMed Web of Science ®Google Scholar
• Gale CR, Kivimaki M, Lawlor DA, Carroll D, Phillips AC, Batty GD. Fasting glucose, diagnosis of Type 2 diabetes, and depression: the Vietnam experience study. Biol. Psychiatry67, 189–192 (2010).
   PubMed Web of Science ®Google Scholar
• Knol MJ, Heerdink ER, Egberts AC et al. Depressive symptoms in subjects with diagnosed and undiagnosed Type 2 diabetes. Psychosom. Med.69, 300–305 (2007).
   PubMed Web of Science ®Google Scholar
• Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and Type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care31, 2383–2390 (2008).
   PubMed Web of Science ®Google Scholar
• Collins MM, Corcoran P, Perry IJ. Anxiety and depression symptoms in patients with diabetes. Diabetes Med.26, 153–161 (2009).
   PubMed Web of Science ®Google Scholar
• Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol.3, 169–178 (2004).
   PubMed Web of Science ®Google Scholar
• Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol.61, 661–666 (2004).
   PubMed Web of Science ®Google Scholar
• Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: misleading, but manageable. Clin. Interv. Aging3, 383–389 (2008).
   PubMed Web of Science ®Google Scholar
• Willlams CM. Using medications appropriately in older adults. Am. Fam. Phys.66, 1917–1924 (2002).
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on Type 2 diabetes mellitus: an algorithm for glycemic control. Endocr. Pract.15, 540–559 (2009).
   PubMed Web of Science ®Google Scholar
• Holstein A, Beil W. Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions. Exp. Opin. Drug Metab. Toxicol.5, 225–241 (2009).
   PubMed Web of Science ®Google Scholar
• Holstein A, Hahn M, Patzer O, Seeringer A, Kovacs P, Stingl J. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. Eur. J. Clin. Pharmacol.67, 471–476 (2011).
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Drug–drug and food–drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin. Pharmacokinet.46, 93–108 (2007).
   PubMed Web of Science ®Google Scholar
• Weiss J, Sauer A, Herzog M, Boger RH, Haefeli WE, Benndorf RA. Interaction of thiazolidinediones (glitazones) with the ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein. Pharmacology84, 264–270 (2009).
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Dipeptidylpeptitase-4 inhibitors (gliptins): focus on drug–drug interactions. Clin. Pharmacokinet.49, 573–588 (2010).
   PubMed Web of Science ®Google Scholar
• Wang C, Li J, Lv X et al. Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin. Eur. J. Pharmacol.620, 131–137 (2009).
   PubMed Web of Science ®Google Scholar
• Thomas MC, Atkins RC. Blood pressure lowering for the prevention and treatment of diabetic kidney disease. Drugs66, 2213–2234 (2006).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Morbidity and mortality weekly report: incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes – United States and Puerto Rico, 1996–2007 MMWR Morb. Mortal Wkly Rep.59(42), 1361–1366 (2010).
   PubMedGoogle Scholar
• Gilbert RE, Cooper ME, Krum H. Drug administration in patients with diabetes mellitus. Safety considerations. Drug Saf.18, 441–455 (1998).
   PubMedGoogle Scholar
• Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension19, 403–418 (1992).
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin–receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med.345, 851–860 (2001).
   PubMed Web of Science ®Google Scholar
• Bell DS. Metformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy. South Med. J.103, 265–267 (2010).
   PubMed Web of Science ®Google Scholar
• Glyburide tablets USP (nonmicronized) 1.25, 2.5 and 5 mg, prescribing information. Sandoz Inc., NJ, USA (2009).
   Google Scholar
• Glucotrol® (glipizide), prescribing information. Pfizer, Inc., NY, USA (2010).
   Google Scholar
• Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia46, 347–351 (2003).
   PubMed Web of Science ®Google Scholar
• Prandin® (repaglinide) tablets (0.5, 1 and 2 mg), prescribing information. Novo Nordisk Inc., Princeton, NJ, USA (2010).
   Google Scholar
• Starlix® (nateglinide) tablets, prescribing information. Novartis Pharmaceuticals, East Hanover, NJ, USA (2011).
   Google Scholar
• Rodbard HW, Blonde L, Braithwaite SS et al. American association of clinical endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr. Pract.13(Suppl. 1), S1–S68 (2007).
   PubMedGoogle Scholar
• Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet.35, 361–390 (1998).
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetic interactions with thiazolidinediones. Clin. Pharmacokinet.46, 1–12 (2007).
   PubMed Web of Science ®Google Scholar
• Simo R, Rodriguez A, Caveda E. Different effects of thiazolidinediones on cardiovascular risk in patients with Type 2 diabetes mellitus: pioglitazone versus rosiglitazone. Curr. Drug Saf.5, 234–244 (2010).
   PubMedGoogle Scholar
• Lecka-Czernik B. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr. Osteoporos. Rep.8, 178–184 (2010).
   PubMedGoogle Scholar
• Januvia® (sitagliptin) tablets, prescribing information. Merck & Co., Inc., NJ, USA (2010).
   Google Scholar
• Onglyza® (saxagliptin) tablets, prescribing information. Bristol-Myers Squibb Company, NJ, USA (2011).
   Google Scholar
• Galuvs® (vildagliptin), prescribing information. Novartis Pharmaceuticals Australia Pty Ltd., NSW, Australia (2011).
   Google Scholar
• Tradjenta™ (linagliptin), prescribing information. Boehringer Ingelheim Pharmaceuticals Inc, CT, USA (2011).
   Google Scholar
• Engel SS, Williams-Herman DE, Golm GT et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int. J. Clin. Pract.64, 984–990 (2010).
   PubMed Web of Science ®Google Scholar
• Levemir® (insulin detemir [rDNA origin] injection), prescribing information. Novo Nordisk, NJ, USA (2010).
   Google Scholar
• Lantus® (insulin glargine [rDNA origin] injection), prescribing information. sanofi-aventis, NJ, USA (2007).
   Google Scholar
• Humalog® (insulin lispro injection, USP), prescribing information. Eli Lilly and Company, IN, USA (2011).
   Google Scholar
• Apidra® (insulin glulisine [rDNA origin] injection) solution for injection, prescribing information. sanofi-aventis U.S. LLC, NJ, USA (2009).
   Google Scholar
• NovoLog® (insulin aspart [rDNA origin] injection), prescribing information. Novo Nordisk, Inc., NJ, USA (2010).
   Google Scholar
• Humulin® R (regular U-500 [concentrated] insulin human injection [rDNA origin]), prescribing information. Eli Lilly, IN, USA (2011).
   Google Scholar
• Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in Type 2 (noninsulin-dependent) diabetic patients. J. Clin. Endocrinol. Metab.81, 327–332 (1996).
   PubMed Web of Science ®Google Scholar
• Nauck MA, Niedereichholz U, Ettler R et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol. Endocrinol. Metab.273, E981–E988 (1997).
   PubMed Web of Science ®Google Scholar
• Byetta® (exenatide) injection, prescribing information. Amylin Pharmaceuticals, Inc., CA, USA (2010).
   Google Scholar
• Victoza® (liraglutide [rDNA origin] injection) solution for subcutaneous use, prescribing information. Novo Nordisk, Inc., NJ, USA (2011).
   Google Scholar
• Peterson GE, Pollom RD. Liraglutide in clinical practice: dosing, safety and efficacy. Int. J. Clin. Pract. Suppl.64, 35–43 (2010).
   Google Scholar
• Hogue JC, Lamarche B, Deshaies Y et al. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with Type 2 diabetes mellitus with marked hypertriglyceridemia. Metabolism57, 246–254 (2008).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Corsini A, Davidson MH et al. Risk for myopathy with statin therapy in high-risk patients. Arch. Intern. Med.163, 553–564 (2003).
   PubMed Web of Science ®Google Scholar
• Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atheroscler. Suppl.3, 35–40 (2002).
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther.80, 565–581 (2006).
   PubMed Web of Science ®Google Scholar
• Amsden GW, Kuye O, Wei GC. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J. Clin. Pharmacol.42, 442–449 (2002).
   Google Scholar
• Lau YY, Huang Y, Frassetto L, Benet LZ. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin. Pharmacol.Ther.81, 194–204 (2007).
   PubMed Web of Science ®Google Scholar
• Guay DR. Update on fenofibrate. Cardiovasc. Drug Rev.20, 281–302 (2002).
   PubMedGoogle Scholar
• Brautbar A, Covarrubias D, Belmont J et al. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis doi:10.1016/j.atherosclerosis.2011.08.015 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet366, 1849–1861 (2005).
   PubMed Web of Science ®Google Scholar
• Pruski M, Krysiak R, Okopien B. Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in Type 2 diabetic patients with mixed dyslipidemia. Diabetes Care32, 1421–1424 (2009).
   PubMed Web of Science ®Google Scholar
• Agouridis AP, Filippatos TD, Derdemezis CS, Mikhailidis DP, Elisaf MS. Combination of fenofibrate with non-statin drug regimens. Curr. Pharm. Des.16, 3401–3416 (2010).
   PubMed Web of Science ®Google Scholar
• Triglide® (fenofibrate) tablets, prescribing information. Shionogi Pharma Inc., GA, USA (2010).
   Google Scholar
• King JM, Crouse JR, Terry JG, Morgan TM, Spray BJ, Miller NE. Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia. Am. J. Med.97, 323–331 (1994).
   PubMed Web of Science ®Google Scholar
• Vijayaraghavan K, Deedwania P. Renin–angiotensin–aldosterone blockade for cardiovascular disease prevention. Cardiol. Clin.29, 137–156 (2011).
   PubMed Web of Science ®Google Scholar
• Alsheikh-Ali AA, Karas RH. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). Am. J. Cardiol.99, 379–381 (2007).
   PubMed Web of Science ®Google Scholar
• Bell DS. Treatment of diabetic hypertension. Diabetes Obes. Metab.11, 433–444 (2009).
   PubMed Web of Science ®Google Scholar
• Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotection effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A seven year follow-up study. Arch. Intern. Med.156, 286–289 (1996).
   PubMed Web of Science ®Google Scholar
• Chaturvedi N, Sjolie AK, Stephenson JM et al. Effect of lisinopril on progression of retinopathy in normotensive people with Type 1 diabetes. The EUCLID Study Group. EURODIAB controlled trial of lisinopril in insulin-dependent diabetes mellitus. Lancet351, 28–31 (1998).
   PubMed Web of Science ®Google Scholar
• McLaughlin DM, Atkinson AB, Ennis CN et al. Comparison of effects of combined ACE inhibitor and low-dose thiazide diuretic with ACE inhibitor alone on insulin action in patients with hypertension and Type 2 diabetes: a double-blind crossover study. Diabetes Med.25, 631–634 (2008).
   PubMedGoogle Scholar
• Marcum ZA, Fried LF. Aging and antihypertensive medication-related complications in the chronic kidney disease patient. Curr. Opin. Nephrol. Hypertens.20, 449–456 (2011).
   PubMed Web of Science ®Google Scholar
• Packham DK, Ivory SE, Reutens AT et al. Proteinuria in Type 2 diabetic patients with renal impairment: the changing face of diabetic nephropathy. Nephron Clin. Pract.118, c331–c338 (2011).
   Google Scholar
• Juhlin T, Erhardt LR, Ottosson H, Jonsson BA, Hoglund P. Treatments with losartan or enalapril are equally sensitive to deterioration in renal function from cyclooxygenase inhibition. Eur. J. Heart Fail.9, 191–196 (2007).
   PubMed Web of Science ®Google Scholar
• Deferrari G, Ravera M, Berruti V, Leoncini G, Deferrari L. Optimizing therapy in the diabetic patient with renal disease: antihypertensive treatment. J. Am. Soc. Nephrol.15(Suppl. 1), S6–S11 (2004).
   Google Scholar
• Avapro® (irbesartan) tablets, prescribing information. Bristol-Myers Squibb, NY, USA (2007).
   Google Scholar
• Cozaar® (losartan potassium tablets), prescribing information. Merck & Co., Inc., NJ, USA (2011).
   Google Scholar
• Bakris GL, Fonseca V, Katholi RE et al. Metabolic effects of carvedilol vs metoprolol in patients with Type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA292, 2227–2236 (2004).
   PubMed Web of Science ®Google Scholar
• Tenormin® (atenolol), prescribing information. Astra Zeneca Pharmaceuticals, LP, DE, USA (2011).
   Google Scholar
• Coreg® (carvedilol) tablets, prescribing information. GlaxoSmithKline, Research Triangle Park, NC, USA (2011).
   Google Scholar
• Fonseca VA. Effects of β-blockers on glucose and lipid metabolism. Curr. Med. Res. Opin.26, 615–629 (2010).
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann. Intern. Med.122, 133–141 (1995).
   PubMed Web of Science ®Google Scholar
• Calan® verapamil hydrochloride tablets, prescribing information. Pfizer Inc., NY, USA (2009).
   Google Scholar
• Procardia® (nifedipine) capsules for oral use, prescribing information. Pfizer Inc., NY, USA (2011).
   Google Scholar
• Zocor® (simvastatin), prescribing information. Merck & Co., Inc., Whitehouse Station, NJ, USA (2011).
   Google Scholar
• Mevacor® (lovastatin), prescribing information. Merck & Co., Inc., Whitehouse Station, NJ, USA (2010).
   Google Scholar
• Lasix® (furosemide) tablets 20, 40, and 80 mg, prescribing information. sanofi-aventis, NJ, USA (2011).
   Google Scholar
• Duarte JD, Cooper-DeHoff RM. Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Exp. Rev. Cardiovasc. Ther.8(6), 793–802 (2010).
   PubMedGoogle Scholar
• Schneider M, Lerch M, Papiri M et al. Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive Type 2 diabetes. J. Hypertens.14, 669–677 (1996).
   PubMed Web of Science ®Google Scholar
• Lin G, Hays DP, Spillane L. Refractory hypoglycemia from ciprofloxacin and glyburide interaction. J. Toxicol. Clin. Toxicol.42, 295–297 (2004).
   PubMed Web of Science ®Google Scholar
• Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann. Pharmacother.41, 1859–1866 (2007).
   PubMed Web of Science ®Google Scholar
• Brown TT, Cole SR, Li X et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch. Intern. Med.165, 1179–1184 (2005).
   PubMed Web of Science ®Google Scholar
• Spollett GR. Hyperglycemia in HIV/AIDS. Diabetes Spectr.19, 163–166 (2006).
   Google Scholar
• Crixivan® (indinavir sulfate) capsules, prescribing information. Merck & Co., Inc., NJ, USA (2010).
   Google Scholar